Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024;24(9):895-907.
doi: 10.2174/1389557523666230915103121.

Recent Advances in Nanobiotechnology for the Treatment of Non-Hodgkin's Lymphoma

Shuxian Liu  1 , Minghao Xu  1 , Lei Zhong  2 , Xiangmin Tong  3 , Suying Qian  4
Affiliations
Review

Recent Advances in Nanobiotechnology for the Treatment of Non-Hodgkin's Lymphoma

Shuxian Liu et al. Mini Rev Med Chem. 2024.

Abstract

Lymphoma is the eighth most common type of cancer worldwide. Currently, lymphoma is mainly classified into two main groups: Hodgkin's lymphoma (HL) and non-Hodgkin's lymphoma (NHL), with NHL accounting for 80% to 90% of the cases. NHL is primarily divided into B, T, and natural killer (NK) cell lymphoma. Nanotechnology is developing rapidly and has made significant contributions to the field of medicine. This review summarizes the advancements of nanobiotechnology in recent years and its applications in the treatment of NHL, especially in diffuse large B cell lymphoma (DLBCL), primary central nervous system lymphoma (PCNSL), and follicular lymphoma (FL). The technologies discussed include clinical imaging, targeted drug delivery, photodynamic therapy (PDT), and thermodynamic therapy (TDT) for lymphoma. This review aims to provide a better understanding of the use of nanotechnology in the treatment of non-Hodgkin's lymphoma.

Keywords: B cell lymphoma; cancer.; combination therapy; nano biomaterials; nanobiotechnology; non-hodgkin's lymphoma.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

References

    1. de Leval L.; Jaffe E.S.; Lymphoma classification. Cancer J 2020,26(3),176-185 - DOI - PubMed
    1. Ansell S.M.; Non-hodgkin lymphoma: Diagnosis and treatment. Mayo Clin Proc 2015,90(8),1152-1163 - DOI - PubMed
    1. Violeta Filip P.; Cuciureanu D.; Sorina Diaconu L.; Maria Vladareanu A.; Silvia Pop C.; MALT lymphoma: Epidemiology, clinical diagnosis and treatment. J Med Life 2018,11(3),187-193 - DOI - PubMed
    1. Pan Z.; Xu M.L.; T-cell and NK-cell lymphomas in the lung. Semin Diagn Pathol 2020,37(6),273-282 - DOI - PubMed
    1. Cheng M.; Zain J.; Rosen S.T.; Querfeld C.; Emerging drugs for the treatment of cutaneous T-cell lymphoma. Expert Opin Emerg Drugs 2022,27(1),45-54 - DOI - PubMed

MeSH terms

Substances

LinkOut - more resources